|
|
|
|
J Clin Oncol 2010,Jan,10;28(2):189-91; (PMID: 19996025)
|
|
|
Cancer Prev Res (Phila Pa) 2010,Jan,01;3(1):12-5; (PMID: 20051368)
[...]This perspective on Bellacosa et al. (beginning on p. 48 in this issue of the journal) discusses the important biology of microscopically normal tissues in carriers of germ-line BRCA1 or BRCA2 mutations. The work of Bellacosa et al. is an important step toward discerning which pathways[...]
|
|
|
J Clin Oncol 2009,Dec,10;27(35):5862-4; (PMID: 19858367)
|
|
|
J Genet Couns 2009,Dec,01;18(6):527-9; (PMID: 19760496)
|
|
|
Breast Cancer Res 2009,Jan,01;11(6):111; (PMID: 20017885) [FULL TEXT AVAILABLE]
[...]) inhibitors have been explored as therapeutic agents for the treatment of hereditary breast and ovarian cancers harboring mutations in BRCA1 or BRCA2. In a new study, Inbar-Rozensal and colleagues show that phenanthridine-derived PARP inhibitors promote [...]cell cycle arrest and cell death in breast cancer cells lacking BRCA1 and BRCA2 mutations and prevent the growth of tumors from xenografts of these cells in immunocompromised mice.[...]
|
|
|
J Med Genet 2008,Nov,01;45(11):765-6; (PMID: 18978334)
|
|
|
J Med Genet 2008,Jul,01;45(7):409-10; (PMID: 18456714)
|
|
|
Cancer 2007,Dec,15;110(12):2819; author reply 2819-20; (PMID: 17969078)
|
|
|
N Engl J Med 2007,Oct,11;357(15):1555; author reply 1556; (PMID: 17928608)
|
|
|
N Engl J Med 2007,Oct,11;357(15):1555-6; author reply 1556; (PMID: 17933033)
|
 1 2 3 4 
|
|
